2026 / 05

DOI: 10.24075/brsmu.2026.051
Copyright: © 2026 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Long-term outcomes of the trial of the RAS-GTPase inhibitor (“Ing-Ras”) efficacy in advanced gastric and colon tumors

Kulinich TM , Kudinova EA , Goncharov SV , Kukoleva EA , Puchkov IA , Chaptykov AA , Dovgan FN , Goncharova OI , Bozhenko VK
About authors

Russian Scientific Center for Roentgenoradiology, Moscow, Russia

Correspondence should be addressed: Tatiana M. Kulinich
Profsoyuznaya, 86, Moscow, 117997, Russia; ur.liam@larbos

About paper

Funding: the study was conducted with financial support from the Ministry of Health of the Russian Federation, the State Task project No. 1023021500033-4-3.2.21;3.1.5.

Author contribution: Kulinich TM — research design, analysis of results, manuscript writing; Kudinova EA — clinical trial plan and procedure, assessment of results; Goncharov SV, Kukoleva EA, Chaptykov AA — implementation of main clinical trial procedures; Puchkov IA — monitoring the trial progress, interpretation of results, manuscript writing; Dovgan FN — analysis of results, manuscript writing; Goncharova OI — contribution to the clinical trial, assessment of results; Bozhenko VK — developing the research design, statistical analysis and assessment of results, manuscript writing.

Compliance with ethical standards: the study was approved by the Ethics Council of the Ministry of Health of the Russian Federation (protocol No. 325 dated 17 January, 2023), initial approval of the Ministry of Health of the Russian Federation to conduct the clinical trial No. 177 dated 30 March, 2023 was obtained. The study was approved by the Ethics Committee of the Russian Scientific Center of Roentgenoradiology (protocol No. 4 dated April 28, 2023). All patients submitted the informed consent to take part in the study.

Received: 2026-08-18 Accepted: 2026-09-10 Published online: 2026-09-20
|
  1. Trishchenkov S, Lyovina O, Nekoval V, Balaban V, Carkov P. Peritoneal'nyj kanceromatoz u bol'nyh mestnorasprostranennym rakom tolstoj kishki: obzor literatury. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2025; 35 (3): 21– 32. Russian.
  2. Feng J, Zhang L, Liao Z, Zou Y, Liu R. Tumour immune cell infiltration and response to FOLFOX or FOLFIRI chemotherapy in colorectal cancer. The Pharmacogenomics Journal. 2026; 26 (2): 9.
  3. Solodkij V, Fomin D, Goncharov S, Kukushkina S. Sovremennye podhody k lecheniyu peritoneal'nogo kanceromatoza pri rake zheludka (obzor literatury). Sibirskij onkologicheskij zhurnal. 2022; 21 (1): 122–9. Russian.
  4. Daniel SK, Sun BJ, Lee B. PIPAC for gastrointestinal malignancies. Journal of Clinical Medicine. 2023; 12 (21): 6799.
  5. Sun BJ, Lee B. Review of regional therapies for gastric cancer with peritoneal metastases. Cancers. 2022; 14 (3): 570.
  6. Robella M, Hubner M, Sgarbura O, Reymond M, Khomiakov V, Di Giorgio A, et al. Feasibility and safety of PIPAC combined with additional surgical procedures: PLUS study. European Journal of Surgical Oncology. 2022; 48 (10): 2212–7.
  7. Brebu D, Faur FI, Selaru M, Cireap N, Burta C, Braicu V, et al. Pressurized Intraperitoneal Aerosol Chemotherapy for Platinum-Resistant Ovarian Cancer: A Systematic Review and Meta-Analysis of Clinical Outcomes. Journal of Clinical Medicine. 2026; 15 (12): 4443.
  8. Di Giorgio A, Macri A, Ferracci F, Robella M, Visaloco M, De Manzoni G, et al. 10 years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis. Cancers. 2023; 15 (4): 1125.
  9. Sha M, Gao Y, Yin X, Li X, Liu C, Li S. Engineered exosomes: a promising approach for overcoming challenges in pancreatic cancer therapy. Journal of Nanobiotechnology. 2025; 23 (1): 619.
  10. Jadhav K, Abhang A, Kole EB, Gadade D, Dusane A, Iyer A, et al. Peptide–drug conjugates as next-generation therapeutics: exploring the potential and clinical progress. Bioengineering. 2025; 12 (5): 481.
  11. Stenvall A, Gustafsson J, Larsson E, Roth D, Sundlöv A, Jönsson L, et al. Relationships between uptake of [68Ga] Ga-DOTA-TATE and absorbed dose in [177Lu] Lu-DOTA-TATE therapy. EJNMMI research. 2022; 12 (1): 75.
  12. Zhang D, Huang G, Liu J, Wei W. Claudin18. 2-targeted cancer theranostics. American journal of nuclear medicine and molecular imaging. 2023; 13 (2): 64.
  13. Bozhenko VK, Kulinich TM, Randzhit R, Ivanov AV, SHishkin AM, Kiselyova YAYU, et al. Farmakokinetika peptidnogo ingibitora Ras-GTFazy «Ing-Ras». Vestnik Rossijskogo nauchnogo centra rentgenoradiologii Minzdrava Rossii. 2023; 23 (4): 9–22. Russian.
  14. Kulinich T, Kudinova E, Ivanov A, SHishkin A, Kaminskij V, Knyazeva O, et al. Issledovanie protivoopuholevoj effektivnosti peptidnogo ingibitora Ras-GTFazy («Ing-Ras») na ksenograftnoj modeli nemelkokletochnogo raka legkogo. Vestnik Rossijskogo nauchnogo centra rentgenoradiologii Minzdrava Rossii. 2024; 24 (4): 38–47. Russian.
  15. Colorectal Cancer — Cancer Stat Facts. SEER (Surveillance, Epidemiology, and End Results Program), 2026. Available from: https://seer.cancer.gov/statfacts/html/colorect.html.
  16. Stomach Cancer — Cancer Stat Facts. SEER (Surveillance, Epidemiology, and End Results Program), 2026. Available from: https://seer.cancer.gov/statfacts/html/stomach.html (data obrashcheniya: 17.08.2026).
  17. Stomach Cancer — Cancer Stat Facts. NCI SEER (National Cancer Institute, Surveillance, Epidemiology, and End Results Program), 2025. Available from: https://seer.cancer.gov/statfacts/html/stomach.html (дата обращения: 17.08.2026).
  18. Survival | Bowel cancer. Cancer Research UK, 2025. Available from: https://www.cancerresearchuk.org/about-cancer/bowel-cancer/survival (дата обращения: 17.08.2026).
  19. Survival for stomach cancer. Cancer Research UK. Available from: https://www.cancerresearchuk.org/about-cancer/stomach-cancer/survival (дата обращения: 17.08.2026).
  20. Kaprin AD. Zlokachestvennye novoobrazovaniya v Rossii v 2024 godu (zabolevaemost'). M.: MNIOI im. P. A. Gercena — filial FGBU «NMIC radiologii» Minzdrava Rossii, 2025; 178 s. Russian.
  21. Kaprin VV, Starinskij AO, Shahzadova AD. Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2023 godu. M.: MNIOI im. P. A. Gercena — filial FGBU «NMIC radiologii» Minzdrava Rossii, 2024; 167 s. Russian.
  22. Colorectal Cancer Survival Rates | Colorectal Cancer Prognosis. American Cancer Society. Available from: https://www.cancer. org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html.
  23. Stomach (Gastric) Cancer Survival Rates. American Cancer Society, 2026. Available from: https://www.cancer.org/cancer/types/stomach-cancer/detection-diagnosis-staging/survival-rates.html (data obrashcheniya: 17.08.2026).
  24. Stomach (Gastric) Cancer Survival Rates. American Cancer Society, 2025. Available from: https://www.cancer.org/cancer/types/stomach-cancer/detection-diagnosis-staging/survival-rates.html (data obrashcheniya: 17.08.2026).
  25. Cancer Facts & Figures 2026. American Cancer Society. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2026-cancer-facts-figures.html (data obrashcheniya: 17.08.2026)
  26. Siegel RL, Wagle NS, Star J, Kratzer TB, Smith RA, Jemal A. Colorectal cancer statistics, 2026. CA Cancer J Clin. 2026; 76 (2): e70067. DOI: 10.3322/caac.70067 PubMed PMID: 41769777.
  27. Balboa-Barreiro V, Pértega-Díaz S, García-Rodríguez T, González-Martín C, Pardeiro-Pértega R, Yáñez-González-Dopeso L, et al. Colorectal cancer recurrence and its impact on survival after curative surgery: An analysis based on multistate models. Digestive and Liver Disease. 2024; 56 (7): 1229–36.
  28. Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, et al. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer. Molecular cancer. 2024; 23 (1): 61.
  29. Lara MAR, Esposito MI, Aineseder M, Grove RL, Cerini MA, Verzura MA, et al. Radiomics and Machine Learning for prediction of two-year disease-specific mortality and KRAS mutation status in metastatic colorectal cancer. Surgical Oncology. 2023; 51: 101986.
  30. Marcellinaro R, Spoletini D, Grieco M, Avella P, Cappuccio M, Troiano R, et al. Colorectal cancer: current updates and future perspectives. Journal of Clinical Medicine. 2023; 13 (1): 40.
  31. Swartjes H, van Rees JM, van Erning FN, Verheij M, Verhoef C, de Wilt JH, et al. Locally recurrent rectal cancer: toward a second chance at cure? A population-based, retrospective cohort study. Annals of surgical oncology. 2023; 30 (7): 3915–24.
  32. Martínez-Pérez J, Valladares-Ayerbes M. KRAS G12C inhibitors in metastatic colorectal cancer: a tale of two targets. Transl Gastroenterol Hepatol. 2024; 9: 54. DOI: 10.21037/tgh-24-48 Epub 20240829. PubMed PMID: 39503027.
  33. He M, Chen Z-f, Liu S, Chen Y, Zhang H, Zhang L, et al. Deep learning model based on multi-lesion and time series CT images for predicting the benefits from anti-HER2 targeted therapy in stage IV gastric cancer. Insights into Imaging. 2024; 15 (1): 59.
  34. Sundar R, Nakayama I, Markar SR, Shitara K, van Laarhoven HW, Janjigian YY, et al. Gastric cancer. The Lancet. 2025; 405 (10494): 2087–102.
  35. Boute TC, Swartjes H, Greuter MJ, Elferink MA, van Eekelen R, Vink GR, et al. Cumulative incidence, risk factors, and overall survival of disease recurrence after curative resection of stage II– III colorectal cancer: a population-based study. Cancer research communications. 2024; 4 (2): 607–16.
  36. Takeno A, Motoori M, Kishi K, Omori T, Hirao M, Masuzawa T, et al. Prognostic factors of conversion surgery for stage IV gastric cancer: A multi‐institutional retrospective analysis. Annals of Gastroenterological Surgery. 2024; 8 (3): 431–42.
  37. Kodera Y, Yoshida K, Kochi M, Sano T, Ichikawa W, Kakeji Y, et al. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study: Y. Kodera et al. Gastric Cancer. 2023; 26 (6): 1063–8.
  38. Bozhenko VK, Goncharov SV, Kudinova EA, Kulinich TM, Kukoleva EA, Filippov MS, et al. Safety assessment and determination of a maximally tolerated dose of an RAS-GTPase inhibitor (iRAS) in the treatment of gastrointestinal tumors: preliminary results of the phase I trial. Almanac of Clinical Medicine. 2023; 51 (7): 376–96.
  39. Kulinich TM, Kukoleva EA, Goncharov SV, Kudinova EA, Puchkov IA, Goncharova OI et al. Results of a Phase IIa clinical trial of a RAS-GTPase inhibitor (Ing-Ras) for the treatment of gastrointestinal tumors. Bulletin of RSMU. 2025; 6: 37–45. DOI: 10.24075/brsmu.2025.065.
  40. González-Flores E, Garcia-Carbonero R, Élez E, Redondo-Cerezo E, Safont MJ, Vera García R. Gender and sex differences in colorectal cancer screening, diagnosis and treatment. Clinical and Translational Oncology. 2025; 27 (7): 2825–37.
  41. Cohen R, Meurisse A, Pudlarz T, Bennouna J, Tournigand C, De La Fouchardiere C, et al. One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/ mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study. American Society of Clinical Oncology; 2022.
  42. Alyasova A, Efendiev K, Reshetov I, Ilyasova D, Shpileva O, Loschenov V, et al. Current Approaches and Emerging Strategies in the Treatment of Peritoneal Carcinomatosis. Int J Mol Sci. 2026; 27 (15): 6623. DOI: 10.3390/ijms27156623. PMID: 42589281; PMCID: PMC13466377.